amphetamine has been researched along with Parkinson Disease, Postencephalitic in 3 studies
Amphetamine: A powerful central nervous system stimulant and sympathomimetic. Amphetamine has multiple mechanisms of action including blocking uptake of adrenergics and dopamine, stimulation of release of monamines, and inhibiting monoamine oxidase. Amphetamine is also a drug of abuse and a psychotomimetic. The l- and the d,l-forms are included here. The l-form has less central nervous system activity but stronger cardiovascular effects. The d-form is DEXTROAMPHETAMINE.
1-phenylpropan-2-amine : A primary amine that is isopropylamine in which a hydrogen attached to one of the methyl groups has been replaced by a phenyl group.
amphetamine : A racemate comprising equimolar amounts of (R)-amphetamine (also known as levamphetamine or levoamphetamine) and (S)-amphetamine (also known as dexamfetamine or dextroamphetamine.
Parkinson Disease, Postencephalitic: Parkinsonism following encephalitis, historically seen as a sequella of encephalitis lethargica (Von Economo Encephalitis). The early age of onset, the rapid progression of symptoms followed by stabilization, and the presence of a variety of other neurological disorders (e.g., sociopathic behavior; TICS; MUSCLE SPASMS; oculogyric crises; hyperphagia; and bizarre movements) distinguish this condition from primary PARKINSON DISEASE. Pathologic features include neuronal loss and gliosis concentrated in the MESENCEPHALON; SUBTHALAMUS; and HYPOTHALAMUS. (From Adams et al., Principles of Neurology, 6th ed, p754)
| Excerpt | Relevance | Reference |
|---|---|---|
| " Dextroamphetamine in lower dosage also reduced disability by some 17 percent." | 2.64 | Amphetamines in the treatment of Parkinson's disease. ( Asselman, P; Bovill, KT; Marsden, CD; Parkes, JD; Phipps, JA; Rose, P; Tarsy, D, 1975) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Parkes, JD | 1 |
| Tarsy, D | 1 |
| Marsden, CD | 1 |
| Bovill, KT | 1 |
| Phipps, JA | 1 |
| Rose, P | 1 |
| Asselman, P | 1 |
| Mumenthaler, M | 1 |
| Kuhn, R | 1 |
| Taeschler, M | 1 |
| Schoch, J | 1 |
1 review available for amphetamine and Parkinson Disease, Postencephalitic
| Article | Year |
|---|---|
[Clinical aspects and drug therapy of Parkinson's syndrome].
Topics: Amphetamine; Diphenhydramine; Humans; Parasympatholytics; Parkinson Disease; Parkinson Disease, Post | 1966 |
2 trials available for amphetamine and Parkinson Disease, Postencephalitic
| Article | Year |
|---|---|
Amphetamines in the treatment of Parkinson's disease.
Topics: Aged; Amantadine; Amphetamine; Clinical Trials as Topic; Female; Humans; Isomerism; Levodopa; Male; | 1975 |
[Pharmacologic and clinical properties of a new butyrophenone derivative (FR 33)].
Topics: Adult; Amphetamine; Animals; Antidepressive Agents; Butyrophenones; Catalepsy; Catatonia; Clinical T | 1966 |